Cequent Pharmaceuticals, Inc is developing new clinically compatible RNAi-based therapies.

15 April 2009

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the
American Association for Cancer Research.

Click Here for Press Release

 

12 February 2009

Cequent Releases Primate Safety, Efficacy Data for Oral FAP Therapy (RNAi News). Click Here for Article

 

12 January 2009

Cequent Names Ted Hibben Chief Business Officer.

Click Here for Press Release

 

Watch Cequent Animation - Click Here!